A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
← catalyst calendarNCT06111235 · readout ≤ 103 d
Sponsored by CG Oncology, Inc. (industry) · CGON — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
367actual
Sites
95
Countries
Canada, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-12-14 | actual | When the study began enrolling |
| Primary completion | Nov 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Feb 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2023-11-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Non Muscle Invasive Bladder Cancer
- Urologic Cancer
- Bladder Cancer
- Urothelial Carcinoma
Interventions
- Drug: Cretostimogene Grenadenorepvec — also filed as CG0070
- Other: n-dodecyl-B-D-maltoside — also filed as DDM
Primary outcome
what the primary-completion date above is the date OFRecurrence Free Survival (RFS)
measured 29 months
Publications
- PMID 27317986 — cited as background
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · CGON's whole pipeline · Catalyst calendar · Every registered study · What changed